Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments

JAMA

Volumn 292, Issue 6, 2004, Pages 721-725

  Melese, Muluken ^a   Chidambaram, Jaya Devi ^b   Alemayehu, Wondu ^a   Lee, David Chung ^b   Yi, Elizabeth H ^b   Cevallos, Vicky ^b   Zhou, Zhaoxia ^b   Donnellan, Cathy ^b   Saidel, Michael ^b   Whitcher, John P ^b,c   Gaynor, Bruce D ^b,c   Lietman, Thomas M ^b,c  

^a ORBIS INTERNATIONAL   (Ethiopia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; EYE OINTMENT; TETRACYCLINE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHLAMYDIA TRACHOMATIS; COHORT ANALYSIS; ERADICATION THERAPY; FEASIBILITY STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PLANNING; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REINFECTION; SINGLE DRUG DOSE; TRACHOMA; ANTIBIOTIC PROPHYLAXIS; CONJUNCTIVITIS; DEVELOPING COUNTRY; ETHIOPIA; INFANT; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; PRESCHOOL CHILD;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; CHILD, PRESCHOOL; CHLAMYDIA TRACHOMATIS; CONJUNCTIVITIS, INCLUSION; DEVELOPING COUNTRIES; ETHIOPIA; HUMANS; INFANT; LONGITUDINAL STUDIES;

EID: 3843120993     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.6.721     Document Type: Article

References (27)

1. Taylor HR, Pacqué M, Muñoz B, Greene BM. Impact of mass treatment of onchocerciasis with ivermectin on the transmission of infection. Science. 1990;250:116-118.
2. Henderson DA. Eradication: lessons from the past. Bull World Health Organ. 1998;76(suppl 2):17-21.
3. Farid M. The malaria programme - from euphoria to anarchy. World Health Forum. 1980;1:8.
4. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ. 1998;76(suppl 2):22-25.
5. Wawer MJ, Sewankambo NK, Serwadda D, et al, for the Rakai Project Study Group. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Lancet. 1999;353:525-535.
6. World Health Organization. Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland: World Health Organization; 1997.
7. Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ. 1995;73:115-121.
8. Jones RB, Van der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis. 1990;162:1309-1315.
9. McOrist S. Obligate intracellular bacteria and antibiotic resistance. Trends Microbiol. 2000;8:483-486.
10. Friederich R. Eye disease in the Navajo indians. Ann Ophthalmol. 1982;14:38-40.
11. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 1999;5:572-576.
12. Kacena KA, Quinn SB, Howell MR, Madico GE, Quinn TC, Gaydos CA. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J Clin Microbiol. 1998;36:481-485.
13. Peeling RW, Toye B, Jessamine P, Gemmill I. Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes. Sex Transm Infect. 1998;74:66-70.
14. Morré SA, Meijer CJ, Munk C, et al. Pooling of urine specimens for detection of asymptomatic Chlamydia trachomatis infections by PCR in a low-prevalence population: cost-saving strategy for epidemiological studies and screening programs. J Clin Microbiol. 2000;38:1679-1680.
15. Diamont J, Moncada J, Pang F, et al. Pooling of chlamydial laboratory tests to determine prevalence of trachoma. Ophthalmic Epidemiol. 2001;8:109-117.
16. Saltelli A, Chan K, Scott EM. Sensitivity Analysis. Chichester, England: John Wiley & Sons; 2000.
17. Holm SO, Jha HC, Bhatta RC, et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ. 2001;79:194-200.
18. Bird M, Dawson CR, Schachter JS, et al. Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? J Infect Dis. 2003;187:1669-1673.
19. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630-635.
20. Katz J, Zeger SL, West KP Jr, Tielsch JM, Sommer A. Clustering of xerophthalmia within households and villages. Int J Epidemiol. 1993;22:709-715.
21. Murray DM. Design and Analysis of Group-Randomized Trials. New York, NY: Oxford University Press; 1998.
22. Jha H, Chaudary J, Bhatta R, et al. Disappearance of trachoma in western Nepal. Clin Infect Dis. 2002;35:765-768.
23. Dolin PJ, Faal H, Johnson GJ, et al. Reduction of trachoma in a sub-Saharan village in absence of a disease control programme. Lancet. 1997;349:1511-1512.
24. Hoechsmann A, Metcalfe N, Kanjaloti S, et al. Reduction of trachoma in the absence of antibiotic treatment: evidence from a population-based survey in Malawi. Ophthalmic Epidemiol. 2001;8:145-153.
25. Emerson PM, Cairncross S, Bailey RL, Mabey DC. Review of the evidence base for the "F" and "E" components of the SAFE strategy for trachoma control. Trop Med Int Health. 2000;5:515-527.
26. Gaynor BD, Miao Y, Cevallos V, et al. Eliminating trachoma in areas with limited disease. Emerg Infect Dis. 2003;9:596-598.
27. Fry AM, Jha HC, Lietman T, et al. Secondary effects of mass chemoprophylaxis with azithromycin to eliminate blindness due to trachoma in Nepal: adverse and beneficial effects. Clin Infect Dis. 2002;35:395-402.